• Deal Opens Pathway for Analyte Development
  • Alastair Smith

News & Views

Deal Opens Pathway for Analyte Development

Mar 18 2021

Cancer therapies and diagnostics developer Avacta Group plc has signed an agreement with Biokit, a Werfen Company, to incorporate its Affimer reagents into an in-vitro diagnostic (IVD) product for detection of a key analyte of interest.

Under the licence, Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners, an in-vitro diagnostic (IVD) immunoassay for this analyte. Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.

Details of the agreement were not disclosed.

Dr Marta Palicio, Innovation Director of Biokit commented: "Biokit is very pleased to have reached this agreement with Avacta. The agreement will increase the competitiveness of our customised assay offering for our partners. Avacta’s technology also enables us to innovate our assays with new reagents like Affimer reagents, an alternative to antibodies. We can now move onto the next stage of development, incorporation of this technology into new products. We hope this is the first of many assays containing Affimer reagents which will be developed by Avacta.”


Digital Edition

Lab Asia April 2022

April 2022

In This Edition Chromatography - Achiral Supercritical Fluid Chromatography (SFC) for the Purification of Pharmaceuticals - Equivalent GC systems performance for regulatory method compliance...

View all digital editions

Events

GCxGC Symposium

May 29 2022 Virtual event

Chemspec Europe

May 31 2022 Frankfurt, Germany

ASMS Conference

Jun 05 2022 Minneapolis, MN, USA

PEFTEC 2022

Jun 08 2022 Rotterdam, Netherlands

ChemBio Finland 2022 - NEW DATES

Jun 08 2022 Helsinki, Finland

View all events